48,470
edits
Difference between revisions of "Medical liver disease"
Jump to navigation
Jump to search
m
→Epidemiology/General: w
m (→Hereditary hemochromatosis: w) |
m (→Epidemiology/General: w) |
||
| Line 362: | Line 362: | ||
**One mutation (C282Y mutation) in up to 12.5% of people in populations of northern and central European origin.<ref name=pmid18192769>{{cite journal |author=Weinberg ED |title=Survival advantage of the hemochromatosis C282Y mutation |journal=Perspect. Biol. Med. |volume=51 |issue=1 |pages=98-102 |year=2008 |pmid=18192769 |doi=10.1353/pbm.2008.0001 |url=}}</ref> | **One mutation (C282Y mutation) in up to 12.5% of people in populations of northern and central European origin.<ref name=pmid18192769>{{cite journal |author=Weinberg ED |title=Survival advantage of the hemochromatosis C282Y mutation |journal=Perspect. Biol. Med. |volume=51 |issue=1 |pages=98-102 |year=2008 |pmid=18192769 |doi=10.1353/pbm.2008.0001 |url=}}</ref> | ||
*Onset in males earlier than females (due to menses). | *Onset in males earlier than females (due to menses). | ||
*Mutation thought to confer survival advantage - several theories (increased resistance to TB, S. typhi vs. decr. iron def./incr. iron absorption)<ref name=pmid18192769/> | *Mutation thought to confer survival advantage - several theories (increased resistance to [[TB]], S. typhi vs. decr. iron def./incr. iron absorption)<ref name=pmid18192769/> | ||
*May lead to [[cardiomyopathy#Restrictive cardiomyopathy|restrictive cardiomyopathy]]. | *May lead to [[cardiomyopathy#Restrictive cardiomyopathy|restrictive cardiomyopathy]]. | ||